Palla Pharma Ltd
ASX:PAL
Income Statement
Earnings Waterfall
Palla Pharma Ltd
Revenue
|
16.8m
AUD
|
Cost of Revenue
|
-23.2m
AUD
|
Gross Profit
|
-6.3m
AUD
|
Operating Expenses
|
-17.2m
AUD
|
Operating Income
|
-23.5m
AUD
|
Other Expenses
|
-35.3m
AUD
|
Net Income
|
-58.8m
AUD
|
Income Statement
Palla Pharma Ltd
Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||
Revenue |
4
N/A
|
4
+16%
|
11
+147%
|
15
+39%
|
22
+52%
|
39
+75%
|
47
+19%
|
51
+10%
|
55
+7%
|
40
-27%
|
22
-44%
|
17
-24%
|
|
Gross Profit | |||||||||||||
Cost of Revenue |
(2)
|
(2)
|
(7)
|
(11)
|
(17)
|
(28)
|
(30)
|
(33)
|
(37)
|
(30)
|
(23)
|
(23)
|
|
Gross Profit |
2
N/A
|
2
+1%
|
4
+71%
|
4
0%
|
5
+41%
|
11
+125%
|
16
+43%
|
18
+12%
|
17
-4%
|
10
-44%
|
(1)
N/A
|
(6)
-500%
|
|
Operating Income | |||||||||||||
Operating Expenses |
(17)
|
(18)
|
(14)
|
(14)
|
(16)
|
(20)
|
(21)
|
(20)
|
(20)
|
(20)
|
(18)
|
(17)
|
|
Selling, General & Administrative |
(12)
|
(12)
|
(8)
|
(8)
|
(11)
|
(15)
|
(15)
|
(15)
|
(15)
|
(15)
|
(13)
|
(12)
|
|
Research & Development |
0
|
0
|
(1)
|
(2)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
|
Depreciation & Amortization |
(4)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
|
Other Operating Expenses |
(2)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
|
Operating Income |
(15)
N/A
|
(16)
-1%
|
(11)
+31%
|
(10)
+4%
|
(11)
-5%
|
(8)
+23%
|
(5)
+45%
|
(2)
+64%
|
(3)
-63%
|
(10)
-268%
|
(19)
-96%
|
(24)
-22%
|
|
Pre-Tax Income | |||||||||||||
Interest Income Expense |
(1)
|
(1)
|
(3)
|
(3)
|
(2)
|
(1)
|
(2)
|
(2)
|
(3)
|
(2)
|
(1)
|
(1)
|
|
Non-Reccuring Items |
(10)
|
(8)
|
(0)
|
(2)
|
(4)
|
(2)
|
(1)
|
(2)
|
(2)
|
(0)
|
(13)
|
(33)
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(1)
|
|
Pre-Tax Income |
(26)
N/A
|
(25)
+5%
|
(14)
+43%
|
(15)
-8%
|
(17)
-10%
|
(12)
+28%
|
(7)
+44%
|
(6)
+12%
|
(8)
-30%
|
(13)
-62%
|
(35)
-175%
|
(59)
-69%
|
|
Net Income | |||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(26)
|
(25)
|
(14)
|
(15)
|
(17)
|
(12)
|
(7)
|
(6)
|
(8)
|
(13)
|
(35)
|
(59)
|
|
Net Income (Common) |
(26)
N/A
|
(25)
+5%
|
(14)
+43%
|
(16)
-11%
|
(17)
-8%
|
(11)
+36%
|
(6)
+46%
|
(6)
-7%
|
(8)
-23%
|
(13)
-65%
|
(35)
-176%
|
(59)
-69%
|
|
EPS (Diluted) |
-0.46
N/A
|
-0.44
+4%
|
-0.24
+45%
|
-0.25
-4%
|
-0.21
+16%
|
-0.16
+24%
|
-0.08
+50%
|
-0.07
+13%
|
-0.08
-14%
|
-0.11
-38%
|
-0.26
-136%
|
-0.42
-62%
|